Dornase alfa biosimilar - Eden Biologics
Alternative Names: JHL 1922Latest Information Update: 19 May 2021
Price :
$50 *
At a glance
- Originator JHL Biotech
- Developer Eden Biologics
- Class Antifibrotics; Enzymes; Eye disorder therapies; Recombinant proteins
- Mechanism of Action Deoxyribonuclease I replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 19 May 2021 Discontinued - Phase-I for Cystic fibrosis in Netherlands (unspecified route) (Eden Biologics pipeline, May 2021)
- 28 Mar 2021 No recent reports of development identified for phase-I development in Cystic-fibrosis in Netherlands
- 27 Dec 2018 JHL Biotech plans a phase III trial for Cystic fibrosis in Europe in 2019